Archive | Next Phase Archive RSS feed for this section

Live Panel Schedule for Digital RESI September 2020

3 Sep

By Joey Wong, Investor Research Analyst, LSN

With only one week left, Digital RESI September 2020 is right around the corner! We are very excited to announce the live panel schedule for the conference.

All panels at Digital RESI September will be live-streamed. There will be two live panel sessions each day, starting as early as next week and will continue through the end of the conference, September 8-16. We welcome all Digital RESI September attendees to join and participate in these live sessions. Registered attendees can RSVP via the partnering platform to receive the dial-in information to join. For those who cannot make the live sessions, all the panel videos will be available via the virtual agenda.

It is worth noting that Global Investment and Partnership Panel, sponsored by Onelin Capital, is open to the public (no RESI registration required). Interested readers are welcome to RSVP here and participate in this panel.

Digital RESI September registrants will hear from the leading industry experts about their investment strategies and differentiated approaches, recent investments and areas of interest, and much more. If you haven’t already, register here for RESI September 2020 to participate in these live panels!

Below is the schedule for next week’s live panel sessions:

 

Corporate VC Panel – “The Corporate Landscape Morphed & New Opportunities Abound

Date & Time: Tuesday, September 8, 10:00 – 10:50 am EST

  • Andy Merken (Moderator), Partner and Co-Chair, Life Sciences, Burns & Levinson
  • Lana Ghanem, Managing Director, Hikma Ventures
  • Mark Ralph, Executive Director, Boehringer Ingelheim Venture Fund
  • Tom Gibbs, Director, Debiopharm Innovation Fund

Medtech Strategics Panel“Large Medical Device Firms Seeking External Innovation”

Date & Time: Tuesday, September 8, 12:00 – 12:50 pm EST

  • Geoff Dacosta (Moderator), Director of Business Development and Licensing, Medtronic
  • Christina Salys, Director of New Business development, Intuitive Surgical
  • David Uffer, Senior Partner, Alira Ventures
  • Rupert Winckler, Head of EMEA New Business Development, Olympus Corporation

Health System Partners Panel “Care Providers and Payers Seek New Technologies”

Date & Time: Wednesday, September 9, 12:00 – 12:50 pm EST

  • Cyrll Philip, Principal, Providence Ventures
  • Linda Maxwell, Director, Biomedical Zone
  • Mayank Taneja, Director of Venture Investments, OSF Healthcare Ventures
  • Rajesh Aggarwal, Executive Vice President, Jefferson Strategic Ventures

Seed Funds Panel “Investing in Emerging Science to Pursue High Rewards”

Date & Time: Wednesday, September 9, 2:00 – 2:50 pm EST

  • Gary Gershony (Moderator), Life Science Angels
  • Anya Roy, Head of Illumina Accelerator Cambridge, Illumina Accelerator
  • Jun Deng, Investment Partner, Joyance Partners
  • Nancy Kaufman, CEO, Beacon Capital
  • Prathna Ramesh, Executive Director, Maple Leaf Angels

Oncology Innovation Panel – “The Search for New Approaches to Diagnosing & Treating Cancer”

Date & Time: Thursday, September 10, 12:00 – 12:50 pm EST

  • Steve Yoder (Moderator), Vice President of Business Development, Taiho Oncology
  • Anthony Bajoras, Managing Director, Cancer Fund
  • Barbara Lavery, Chief Program Officer, Alliance for Cancer Gene Therapy
  • Duncan Young, Director of Search and Evaluation Oncology, Business Development & Licensing, AstraZeneca
  • Mark Krul, Partner, Aglala Oncology Fund

Global Investment and Partnership Panel “Asia Firms Looking to Build Global Partnerships”

Date & Time: Thursday, September 10, 8:00 – 8:50 pm EST (Sponsored by Onelin Capital, Open to the public)

  • Judy Lee (Moderator), General Manager, Onelin Capital
  • Haolin Sung, Managing Partner, Chaperone Investment
  • Haruhiko Sugino, Director of Global Business Development, Otsuka Pharmaceuticals
  • Weiyong Sun, Senior Director of Specialty Medicine Search & Evaluation, Daichi Sankyo
  • Yao Li Ho, Senior Director of Business Development, LYFE Capital

Impact Investors Panel – “Life Science Investors Looking for More Than Financial Returns”

Date & Time: Friday, September 11, 12:00 – 12:50 pm EST

  • Lore Gruenbaum (Moderator), Vice President of Therapy Acceleration Program, Leukemia & Lymphoma Society
  • Chris Penland, Vice President of BioPharma Programs, Cystic Fibrosis Foundation
  • Kuldip Dave, Vice President of Research, ALS Association
  • Michael Cole, Founder and General Partner, Global Neurohealth Ventures
  • Paul Larkin, Manager of Research Innovation, Crohn’s and Colitis Foundation

NIH at Digital RESI September

27 Aug

By Gregory Mannix, Chief Conference Officer, Vice President International Business Development, LSN

The Small Business Education and Entrepreneurial Development (SEED) Group at the National Institutes of Health (NIH) is leading a panel at RESI September on the product development pipeline. SEED is advancing the cause of scientific innovation in healthcare through collaborating with the buyers and sellers in life science to enhance relationships, products, and technology. Fundraising CEOs, strategic partners, and investors can take advantage of the opportunity to learn from the SEED team. Read below to learn more about the panel and click here to register for Digital RESI September.

NIH is SEEDing the Product Development Pipeline 

Small Business Education and Entrepreneurial Development (SEED) Group, Changing the Game for Life Science Innovators

SEED supports the NIH innovator community in their efforts to validate the potential health impacts of promising scientific discoveries and advance them into healthcare products that improve patient care and enhance health. Developing products across the biomedical spectrum requires NIH’s collaboration with universities and research institutions, small businesses, trade associations and societies, angel investors, venture capitalists, and strategic partners. SEED leads initiatives that develop these relationships and build opportunities for NIH innovators to further their product development efforts.

Matthew McMahon, PhD, Director, SEED, NIH

Matt leads the SEED Office to accelerate NIH-funded biomedical innovations from bench to bedside. SEED supports a comprehensive translational research ecosystem that includes a national network of academic proof-of-concept centers and a small business program that invests over $1 billion annually in a portfolio of more than 1500 life science companies. SEED also provides technical and entrepreneurial advisory services and builds relationships with business, finance, and healthcare stakeholders to ensure these innovations will impact patients’ lives. Matt has a diverse background in academia, biomedical small business, congressional policy, and NIH program development and management. His previous experience also includes service as the principal scientist for the bionic eye company Second Sight Medical Products and as a staff member on both the United States Senate and House of Representatives committees responsible for science, technology, and innovation policy.

Stephanie Fertig, MBA, HHS Small Business Program Lead, NIH

Ms. Stephanie J. Fertig is the HHS Small Business Program Lead in SEED (Small business Education and Entrepreneurial Development) at the National Institutes of Health (NIH). She currently oversees the Health and Human Services (HHS) Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, which includes the NIH SBIR and STTR programs. The HHS SBIR and STTR programs are congressionally mandated set-aside programs that provide over $1.2 billion dollars per year to small business concerns. Prior to joining SEED, she managed the SBIR and STTR Programs at the National Institute of Neurological Disorders and Stroke (NINDS). During her over 15 years at NIH she has led the development and implementation of multiple programs focused on small businesses and translational research. Ms. Fertig has a Bachelor of Science degree in Chemistry with a major in Physics from the University of Virginia and a Master of Business Administration from the University of Maryland’s Robert H. Smith School of Business.

Chris Sasiela, PhD, Team Lead, Innovator Support, SEED

Dr. Sasiela has over a decade of experience providing support and consultation to academic innovators and small businesses engaged in therapeutic, device, and diagnostic development programs. As the Innovator Support Team Lead in SEED (Small business Education and Entrepreneurial Development) in the Office of Extramural Research at the National Institutes of Health, Chris coordinates the activities of a team of seasoned professionals with experience in product and business strategy, business development, fundraising, partnerships, reimbursement, and regulatory affairs. Chris is passionate about enabling NIH’s innovator community to progress their discoveries as far as science and human biology permit. Starting her career as a researcher, Chris worked in basic research at the University of Southern California and the University of Maryland, and in drug discovery, development, and improvement groups at Baxter, the Department of the Army, and the National Cancer Institute. Chris transitioned from a research to a regulatory career path via an Interagency Oncology Taskforce Fellowship at the US Food and Drug Administration. Continuing her regulatory career path at Social & Scientific Systems, the National Institute of Allergy and Infectious Diseases, and the National Heart, Lung, and Blood Institute, Chris deepened her experience working with product development researchers understand, develop, and execute regulatory plans to get their innovative technologies from ideas to first-in-human and beyond. She regularly conducts project-focused consultations, delivers educational seminars, and develops regulatory resources for internal and external audiences. Dr. Sasiela earned a bachelor’s degree in chemistry from Whittier College, a Ph.D. in Pharmaceutical Sciences from the University of Maryland, School of Pharmacy, and has maintained Regulatory Affairs Certification status from the Regulatory Affairs Professional Society since 2011.

John Sullivan, MBA, Entrepreneur-in-Residence, SEED

John Sullivan has been a leader in healthcare technology innovation throughout his career, with extensive experience in operating, investing in, developing and acquiring market-leading businesses. Prior to the NIH, John worked with healthcare leaders such as Cardinal Health (VP, Strategy and Business Development) and Boston Scientific. He was a Partner with Foundation Medical Partners, a national healthcare venture capital firm with financial backing from the Cleveland Clinic. He also helped to start Molecular Staging Inc., a biotechnology tools company spun out of Yale University School of Medicine. Working with Yale University founders, he helped grow the company to over 100 employees, develop its product and service lines, and ultimately sell the company to Qiagen, a global life sciences company. He has served on the boards of directors of Semprus Biosciences (acquired, Teleflex), Coapt Systems (acquired, MicroAire), KEW Group, and Direct Flow Medical and held board observer roles at BridgePoint Medical (acquired, Boston Scientific) and Explorys (acquired, IBM). John earned a BS in Industrial Engineering degree with distinction from Stanford University and an MBA from the Stanford University Graduate School of Business.

4D Meets AI’s Angel & Family Office Panel

27 Aug

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

It’s important that fundraising CEOs understand the different types of investors, what differentiates them, and which are the best fits for their products and stage of development. This is why 4D Meets AI is featuring an investor panel on Angels and Family Offices. Many angels and family office groups invest in early-stage life science and healthcare because of the strong impact this capital has on the global market, as well often having a personal connection or mission towards helping in this space. Understanding these groups will give fundraising CEOs a clearer direction when considering strategic partnerships to pursue. Read below to learn more about this panel and click here to register for 4D Meets AI.

Moderator: Dennis Ford, Founder & CEO, Life Science Nation (LSN)

Dennis Ford is an entrepreneur, author, and frontier technologist with deep expertise in sales, marketing, and business development. He has spent most of his career involved in launching new technology-based companies. He has wide-ranging experience in hardware and software computing, middleware, data storage, networking, SaaS, data mining, data profiling, expert systems, and scaling/funding companies. Most recently, Dennis has spent the last 7 years in the early-stage life science arena creating an ecosystem to streamline fundraising for next-generation drugs, devices, diagnostics, and digital health products. Over the last 15 years, he has worked extensively with creating an active network of global investors ranging from Family Offices, Private Equity, Venture Capital, Foundations, and Endowments to large Corporate and Pharmaceutical firms interested in high-growth early-stage technologies. His expertise encompasses using database subscription services to create business solutions and using the Internet to create an interactive dialog between buyers and sellers. He is a big proponent of using data profiling and matching technology to efficiently find that all-important business fit in the marketing and selling process. Currently, Life Science Nation has the most comprehensive life science investor database in the world. Dennis has also pioneered a unique global partnering event model that matches buyers and sellers based on their specifically stated needs and declared partnering mandate initiatives garnered from one-on-one interviews and curating buyer/seller databases in a selected industry. Ford is the author of The Peddler’s Prerogative and The Fund Manager’s Marketing Manifesto, two well-received sales and marketing books. His latest book is The Life Science Executive’s Fundraising Manifesto which he turned into a two-week immersion class for scientist-entrepreneurs and fundraising CEOs which is now offered to international government agencies to move their funded startups into the global funding arena.

Richard Anders, JD, Founder & Executive Director, Mass Medical Angels

Richard Anders is an investor and long-time entrepreneur. He founded the legal software publishing company Jurisoft, which he sold to Lexis/Nexis, published newspapers including Boston Digital Industry and New York Digital Industry and currently serves as managing director of Rubin/Anders Scientific, which places scientists as consultants in patent projects. He has invested in approximately two dozen early-stage startups.

Anders is an overseer at the Museum of Science in Boston where he served as a trustee for nearly 20 years. At the museum he was most recently a member of the food committee, exploring science education around the issues of food and its preparation. He is a trustee of the Forsyth Institute and an overseer at the Brigham & Women’s Hospital and the Gardner Museum. Anders founded and currently runs MA Medical Angels (MA2), one of the country’s leading angel groups focused exclusively on life sciences. He has founded the angel group Launchpad, the nationally renowned Science on Screen event at the Coolidge Corner Cinema and was a founding trustee of the Massachusetts Interactive Media Council. He served for many years as a member of the Dana Farber Cancer Center Institutional Review Board. He has been a board member or board observer at multiple life science startups. Anders teaches medical device entrepreneurship at the Harvard/MIT HST program. He is a graduate Summa Cum Laude in Mathematics from Harvard and holds a J.D. from Harvard Law School.

Ruchi Dana, MD, Board Member, DANA Group of Companies

Dr. Ruchi Dana is a qualified medical practitioner, who has transitioned successfully into a seasoned entrepreneur and Business Leader. Ruchi did her MD from AMU and her full-time MBA from Stanford University. Ruchi also received her PMP Certificate in Public Management and Social Innovation from Stanford University. Ruchi is a frequent speaker at various industry conferences and sits on multiple Corporate, startup, non-profits and University boards including Dana Group of Companies, Dubai, Duluth Medical Technologies Inc, USA, NGO Aaroogya Foundation, India and the California State University, Chico Cybersecurity Advisory Board. Ruchi has been recognized by Forbes Middle East as the “Next Generation Business Leader, Arab World” for 3 consecutive years 2017, 2018 and 2019. She has also been recognized by Campden Wealth as the “Women to Watch” in September’18 issue, and was conferred with the Yuva Ratna Award, 2018. Ruchi has also been recognized as “Top 75 Family Business Leaders” 2019 by Campden Research (UK). Recently, Dr Ruchi was featured on the Forbes ME Top Power Businesswomen 2020. Since joining Dana Group, Ruchi has been instrumental in starting the Value-added Steel manufacturing division in 2008, Lubricants and Grease manufacturing division and also Retail, Hospital and Real Estate divisions for Dana Group in 2014. Dr. Ruchi is actively involved in strategic planning for Dana Group and manages the family office investments. Ruchi has also worked with Golden Seeds, an investment firm in New York and New Silk Route Growth Capital, a PE firm in Dubai, she has mainly focused on healthcare related investments at both these firms.

Michael Langer, Founding Partner, Old Silver VC

Michael is Head of Search, Evaluation and In-licensing for all new technology and products at Pear Therapeutics. Michael also runs point on telemedicine and virtual care transactions, as well as competitive intelligence at Pear. In addition, he works closely with the Pear fundraising team to build and maintain relationships with prospective investors primarily on the international front. Michael is an investor, advisor and mentor to startups. Michael is the founding partner at a fund through his family called Old Silver VC, where he invests in Healthcare (Biotech and DigitalHealth) and Deep Tech with a focus on materials startups. He also invests directly into Seed and/or Healthcare/Biotech focused venture capital funds as a Limited Partner. He is a mentor and Judge at MassChallenge Healthtech and a mentor at MassConnectDH. Michael is an active philanthropist. He co-founded the Young Coder’s Society which teaches children how to code using Raspberry Pi. He is a World Economic Forum Global Shaper, serves on The Discoverers Committee at the Museum of Science, the Visionaries Circle at The Possible Project and is the Senior Advisor of Special Projects at the Galenus Foundation. Prior to Pear and Old Silver VC, Michael spent time at several startups/venture capital funds including: Akili Interactive Labs, Udacity, Modern Meadow, Polaris Partners, The Harvard Experiment Fund and Boston Seed Capital. Michael has a BA from Lehigh University in Science, Technology and Society with a Double Minor in Entrepreneurship and Sustainable Development.

Wei Tao, PhD, Member, Life Science Angels

Wei Tao, PhD, is a Silicon Valley based investor passionate about venture investment. Dr Tao focuses on early stage life science and healthcare companies with explosive growth potential, commercializing disruptive technology to address critical unmet needs and improve societal well-being. Dr. Tao is a sought-after value-add investor and adviser. He built extensive connections with the entrepreneurial community in Silicon Valley and beyond. Dr. Tao is an adviser to a number of entrepreneurship initiatives at leading institutions such as Stanford University, UC Berkeley and UCSF. As a result he enjoys unparalleled access to proprietary deal flow, screening hundreds of promising deals every year. He is an active member of Life Science Angels, the premier life science focused investment group. He served on the board of LSA and several venture-backed companies.

4D Meets AI Panel Spotlight: AI Helping Manage Chronic Disease

20 Aug

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

The AI Helping Manage Chronic Diseases panel at 4D Meets AI discusses the detection, prevention, and intelligent agents treating and managing the stages inherent in chronic disease. AI is supporting increased data volume, improving personalized therapy for patients, in addition to providing more access to patients for daily management. The panel covers a diverse range of chronic disease and solutions providing clinicians with up-to-date information for optimal therapeutic decision-making and patients with the information they need to live happy and healthy lives.

The pre-recorded panel will be part of 4D Meets AI digital partnering conference, taking place September 17-18, 2020.

Moderator: Rick Berenson, CEO, Thermalin

Artificial intelligence (AI) and sensor technology used in implantable and wearable devices and managed care solutions use smart, natural language-based agents to help clinicians and patients with chronic disease management. Rick co-founded Thermalin, which is developing the StampPump – a postage-stamp-sized, wearable, intelligent glucose management system for people with T1 and T2 diabetes. As a connected sensor platform, StampPump will deliver continuous metabolic telemetry that, with the assistance of machine learning algorithms, will enable physicians to better coach diabetes patients and fine-tune their glucose control algorithms. Rick raised the funding, built the scientific and business teams, and drives the company’s strategy. Rick received a JD-MBA from Harvard Business and Law Schools in 1984, then worked for Bell Laboratories and an AI startup before joining McKinsey & Company. He subsequently became a serial entrepreneur who has previously launched and financed multiple life science organizations.

Paul Pyzowski, Founder & CEO, Altimate Health
Paul Pyzowski is the founder and CEO of Altimate Health. Altimate is leading the development of precision psychiatry, applying data science to identify and guide treatment for patients with psychiatric and other behavioral health disorders. Paul has a diverse entrepreneurial and executive background that includes Parkinson’s disease therapeutics, therapies for pediatric epilepsy, rapid DNA sequencing, clinical laboratories for addiction medicine, and computational physics. BSEE from Carnegie-Mellon, MBA from the Institute for Management Development in Switzerland.

Kim Shah, MBA, CEO, KnowYourMeds
Shah was most recently Global Director of Marketing for the Informatics Software business within Thermo Fisher Scientific, a $20 Billion company whose mission is to enable their customers to make the world healthier, cleaner and safer. During his career, Shah has held executive level positions at a number of high-tech companies such as Lotus Development, Micrografx and Inso Corporation. Shah is an experienced Marketing Executive with a demonstrated history of working in the research industry. Skilled in Product Management, Advertising, Enterprise Software, Sales, Entrepreneurship, and Customer Relationship Management (CRM). Strong marketing professional with an MBA focused in Business Administration from MIT Sloan School.

Karolina Starczak, MS, CEO, Nutrimedy
Karolina is currently the CEO of Nutrimedy, a digital health solution focused on transforming clinical nutrition care in oncology, heart failure, kidney disease, and inflammatory bowel disease. As a registered and licensed clinical dietitian, Karolina incorporates her multi-dimensional background in healthcare to uncover innovative solutions aimed at addressing cost drivers and improving health outcomes. Over the past 15 years, her career evolved from the emergency services field to digital startups and workplace wellness. From small local employers to Fortune 500 companies, Karolina has led and designed data-driven, award-winning programs that improve employee wellbeing and help curtail future healthcare spend. Karolina received her BS in Nutrition and Food Science from Montclair State University, completed her post-baccalaureate dietetic residency at Rutgers University, and completed her Master in Healthcare Leadership at Brown University.

RESI September Panel Spotlight: Digital Health Investors

20 Aug

By Karen Deyo, Senior Investor Research Analyst, LSN

There has been a large paradigm shift in healthcare delivery this calendar year and adapting to this digital age will require adoption of new technologies, providing a great opportunity for up-and-coming digital health companies to showcase themselves. At our upcoming Digital RESI conference taking place September 14-16, the panelists will discuss how investing in digital health has changed, which technologies are gaining the most traction, and how to approach investors in the current industry landscape.

We are happy to introduce the speakers participating on the Digital Health Investors panel!

Moderator: Robert Garber, Partner at 7wire Ventures

For over 25 years, Robert Garber has worked with early-stage healthcare and technology companies, co-managing three venture funds with $200M+AUM and holding leadership positions with three high-growth companies. Robert is currently a Partner at 7wire Ventures, where he focuses on investments in digital healthcare and technology-enabled services that empower consumers to be better stewards of their health and healthcare expenditures. 7wireVentures is an early stage, healthcare venture firm that supports entrepreneurs who focus on empowering the Connected Informed Health Consumer to create great companies and change the status quo. 7wire believes that mobile, connected platforms, the cloud, and sophisticated insights will improve the efficiency of the healthcare system and improve outcomes for all.

Evan Cohen, Associate Principal, Strategic Investing at Healthbox

Evan is part of the investment team for the DaVita Venture Fund. Previously, he led M&A and strategic payer activities at Genoa Healthcare (OptumRx division), the country’s leading behavioral health pharmacy, telepsychiatry and medication management services company. Evan joined Genoa Healthcare through the acquisition of 1DocWay, where
he managed clinic-based telepsychiatry sales. He was formerly a healthcare investment banker at Piper Jaffray, where he advised biopharmaceutical, medical device, and healthcare services companies on capital raising and M&A transactions. Evan began his career at BlackRock, where he served as a fixed income product specialist managing institutional client business totaling nearly $100B AUM. Evan resides in New York City and received his BA in Economics from Northwestern University and his MBA from Columbia Business School.

Roy Wiesner, Managing Director at aMoon Fund

Roy Wiesner is a Managing Director at aMoon Fund, Israel’s largest life sciences and healthtech VC. He focuses on early-stage investments, primarily in digital health and medical devices. Prior to joining aMoon, he was the CEO of a Cleantech incubator and seed-stage fund owned by CK Hutchison (Fortune 500 company), where he was also involved in forming a number of ventures. Roy was previously a corporate lawyer, specializing in M&A, Private Equity and VC transactions, working for international law firm Weil Gotshal in New York and Hong Kong, and as a partner for a prominent law firm in Tel Aviv. He holds an LL.B from the Hebrew University and a dual MPA from the LSE and Columbia University.

Ben Evans, Investment Director at InHealth Ventures

Ben started his career as a doctor in the NHS before working in the UK and US across early stage medtech, management consultancy and hospital management. He has a particular interest in technologies that can improve the working lives of clinical and non-clinical healthcare staff.

 

Netalie Nadivi, Partner at TriVentures

Netalie has 20 years of professional experience in technology start-up and global corporate environments. Netalie’s interdisciplinary and holistic background, working with start-ups from different vantage points throughout her career, contributes greatly to the evaluation and identification of investment opportunities and portfolio management.

Netalie spent over a decade at Philips in various corporate capacities including Director of Business Development and M&A. She brings with her tremendous transaction and project management experience in investments, strategic partnerships, acquisitions and post-merger integration spanning across several industries including healthcare and consumer health and wellness.

Prior to her time at Philips, Netalie gained experience in a technology start-up and an accelerator that set up companies from stage zero. In both positions, Netalie held senior multidisciplinary CEO support roles where she was responsible for the companies’ business, legal and financial affairs.

Netalie holds a M.S. in Management from Boston University and a B.A. in Legal Studies from the University of California at Berkeley.

This panel will be live-streamed on Wednesday, September 16, 2020 at 2:00 pm EDT – Make sure to register for RESI to join this and other exciting panels!

Welcome to the Mandate

20 Aug

By Rory McCann, Marketing Manager & Conference Producer, LSN

An investor mandate is a brief description of what firms are most actively searching for and pursuing within their theme. The Mandate is a daily 3-week pop-up newsletter highlighting the latest in AI investor and partnership mandates curated by the research team at Life Science Nation (LSN). It also features the investors and CEOs presenting at the 4D Meets AI digital partnering conference. The Mandate newsletter will bring the latest mandates straight to your inbox leading up to the 4D Meets AI digital partnering conference. 4D Meets AI partnering is new and needed – and LSN has a successful track record connecting buyers and sellers through the Redefining Early Stage Investments (RESI) conference series and are extending that into the AI industry as it pertains to drugs, devices, diagnostics, and digital health (the 4Ds). If you want to sign up for The Mandate, subscribe here.

Check Out Our Digital RESI September Panel Line Up!

13 Aug

By Claire Jeong, Vice President of Investor Research, Asia BD, LSN

claire

With one month left until the next Digital Redefining Early Stage Investments (RESI) September Conference (September 14-16), we are very excited to highlight some of the key speakers who will be contributing to our virtual panels.

These speakers are all investors and strategic partners who actively invest in and work with early-stage life science and healthcare companies, with diverse interests within therapeutics, medical devices, diagnostics, and digital health.

Digital RESI September registrants get to hear from the leading industry experts about their investment strategies and differentiated approaches, recent investments and areas of interest, and more.

Here are some of the panelists joining us:


Jun Deng
Investment Partner
Joyance Partners

Prathna Ramesh
Executive Director
Maple Leaf Angels (MLA)

Nancy Torres Kaufman
CEO
Beacon Capital

Steve Yoder
Vice President, Business Development
Taiho Oncology Inc

Duncan Young
Director, Search and Evaluation Oncology, BD&L
AstraZeneca

Barbara Lavery
Chief Program Officer
Alliance for Cancer Gene Therapy

Mark Krul
Partner
Aglaia Oncology Funds

Weiyong Sun
Senior Director, Specialty Medicine Search & Evaluation
Daiichi Sankyo

Fiona Mack
Head of JLABS TMCx
Johnson & Johnson Innovation

Chris Haskell
VP, Head of West Coast Innovation Center
Bayer

Yao Li Ho
Senior Director of Business Development
LYFE Capital

Haolin Sung
Managing Partner
Chaperone Investment

Christina Salys
Sr. Mgr. New Business Development
Intuitive Surgical

Rupert Winckler
Head of EMEA New Business Development
Olympus Corporation

William Dai
Founding Partner
ShangBay Capital

Benedikt Luhmann
Principal – Healthcare
VI Partners

Norm Gitis
Founder, Managing Partner
Lymo Ventures

Paul Larkin
Manager, Research Innovation
Crohn’s and Colitis Foundation

Michael Cole
Founder and General Partner
Global Neurohealth Ventures

Lore Gruenbaum
Vice President, Therapy Acceleration Program
Leukemia & Lymphoma Society (LLS)

Kuldip Dave
Vice President of Research
ALS Association

Chris Penland
VP BioPharma Programs
Cystic Fibrosis Foundation

Mayank Taneja
Director of Venture Investments
OSF Healthcare Ventures

Cyril Philip
Principal
Providence Ventures

Rajesh Aggarwal
Executive Vice President
Jefferson Strategic Ventures

Linda Maxwell
Director
Biomedical Zone

Ron Paliwoda
Founder and President
Paliwoda Group

Marcia Dawood
Managing Partner
Individual Angel

Merom Klein
Entrepreneur Mentor
Keiretsu Forum

Laura Davis
Managing Director
Golden Seeds

Rob Manning
Chairman
Cherrystone Angel Group

Sascha Berger
Partner
TVM Capital Life Science

Haruhiko Sugino
Director, Global Business Development
Otsuka Pharmaceuticals

Bibhash Mukhopadhyay
Principal
New Enterprise Associates

Jayson Punwani
Senior Partner
Takeda Ventures

Scott Weiner
Partner
Amzak Health

Roy Wiesner
Managing Director
aMoon Fund

Robert Garber
Partner
7wire Ventures

Evan Cohen
Associate Principal, Strategic Investing
Healthbox

Ben Evans
Investment Director
InHealth Ventures

Netalie Nadivi
Partner
TriVentures

Rick Jones
Partner
BioAdvance

Katherine Hill Ritchie
Director
Nottingham Spirk Family Office

Mark Ralph
Executive Director
Boehringer Ingelheim Venture Fund

Please contact RESI@lifesciencenation.com if you are interested in any speaking opportunities!

%d bloggers like this: